Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genotype-Phenotype Relationships in Azole-Resistant <i>Aspergillus</i>: Two Sides of the Same Coin.

Journal of fungi (Basel, Switzerland)·2026
Same author

Characteristics of mycological criteria for the diagnosis of invasive mold infections in patients with severe burn injury.

Journal of clinical microbiology·2026
Same author

Tracing the origin and evolution of specialized biosynthetic pathways in marine organisms.

mBio·2026
Same author

Comparison of gradient concentration strip and EUCAST methods for itraconazole and posaconazole MICs in <i>Trichophyton indotineae</i>.

Antimicrobial agents and chemotherapy·2025
Same author

Metabolic engineering in <i>Nicotiana benthamiana</i>.

aBIOTECH·2025
Same author

The Paclitaxel Biosynthesis Pathway Unlocked.

Research (Washington, D.C.)·2025
Same journal

Impaired gephyrin G-domain trimerization and phase separation in a patient with developmental epileptic encephalopathy.

EMBO molecular medicine·2026
Same journal

Single-nuclei UPR profiling by flow cytometry reveals bortezomib resistance mechanisms in multiple myeloma.

EMBO molecular medicine·2026
Same journal

Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington's disease.

EMBO molecular medicine·2026
Same journal

Bacterialized tumor cells as vaccine.

EMBO molecular medicine·2026
Same journal

Activation of AMPK as a therapeutic strategy for FBXL4-related mitochondrial DNA depletion syndrome.

EMBO molecular medicine·2026
Same journal

Systems serology identifies FcR-related autoantibody signatures and functions for Sjögren's syndrome.

EMBO molecular medicine·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

Innovation in antifungal therapy.

Sarah Dellière1,2, Nicolas Papon3

  • 1Université Paris Cité, AP-HP, Parasitology-Mycology Department, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand-Widal, Paris, France. sarah.delliere@aphp.fr.

EMBO Molecular Medicine
|May 9, 2026
PubMed
Summary
This summary is machine-generated.

Invasive fungal infections are a growing public health concern, especially for immunocompromised patients. Advances in antifungal therapies offer new hope for managing these challenging infections and combating drug resistance.

More Related Videos

Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy
09:06

Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy

Published on: March 29, 2024

Related Experiment Videos

Last Updated: May 11, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy
09:06

Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy

Published on: March 29, 2024

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Immunology

Background:

  • Invasive fungal infections (IFIs) pose a significant public health threat, particularly in immunocompromised individuals.
  • High mortality rates (often >50%) and limited systemic antifungal options complicate patient management.
  • Emerging antifungal resistance due to overuse/misuse in clinical and agricultural settings exacerbates the challenge.

Purpose of the Study:

  • To review recent advances in antifungal therapies for invasive fungal infections.
  • To highlight progress in both pathogen-directed and host-directed treatment strategies.
  • To underscore the need for novel approaches to combat rising IFIs and resistance.

Main Methods:

  • Review of recent literature on medical mycology and antifungal drug development.
  • Analysis of pathogen-directed therapies including new compounds, drug repurposing, and novel targets.
  • Exploration of emerging host-directed immunomodulatory strategies.

Main Results:

  • Significant advancements in identifying new antifungal compounds and drug targets.
  • Development of new formulations and repurposing of existing drugs show promise.
  • Emerging host-directed therapies leveraging immune responses offer new avenues for treatment.

Conclusions:

  • Despite challenges, recent breakthroughs in medical mycology provide hope for improved management of invasive fungal infections.
  • A combination of advanced pathogen-directed and novel host-directed strategies is crucial.
  • Continued research is essential to overcome antifungal resistance and reduce IFI-related mortality.